Next Article in Journal
Differences in Illness Severity among Circulating Norovirus Genotypes in a Large Pediatric Cohort with Acute Gastroenteritis
Next Article in Special Issue
SARS-CoV-2 Inhibition by Sulfonated Compounds
Previous Article in Journal
Gill Mucus and Gill Mucin O-glycosylation in Healthy and Amebic Gill Disease-Affected Atlantic Salmon
Previous Article in Special Issue
Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases
Open AccessArticle

Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro

by 1,2,3,4,†, 1,2,3,†, 3,†, 1,2 and 1,2,3,*
1
Institute of Virology and Immunology, 3147 Mittelhäusern, Switzerland
2
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland
3
Institute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland
4
Graduate School for Molecular Cell Biology, University of Bern, 3012 Bern, Switzerland
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Microorganisms 2020, 8(12), 1872; https://doi.org/10.3390/microorganisms8121872
Received: 30 October 2020 / Revised: 18 November 2020 / Accepted: 24 November 2020 / Published: 26 November 2020
(This article belongs to the Special Issue Recent Advances in Antivirals for Emerging Viruses)
With over 50 million currently confirmed cases worldwide, including more than 1.3 million deaths, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has a major impact on the economy and health care system. Currently, limited prophylactic or therapeutic intervention options are available against SARS-CoV-2. In this study, 400 compounds from the antimicrobial “pandemic response box” library were screened for inhibiting properties against SARS-CoV-2. An initial screen on Vero E6 cells identified five compounds that inhibited SARS-CoV-2 replication. However, validation of the selected hits in a human lung cell line highlighted that only a single compound, namely Retro-2.1, efficiently inhibited SARS-CoV-2 replication. Additional analysis revealed that the antiviral activity of Retro-2.1 occurs at a post-entry stage of the viral replication cycle. Combined, these data demonstrate that stringent in vitro screening of preselected compounds in multiple cell lines refines the rapid identification of new potential antiviral candidate drugs targeting SARS-CoV-2. View Full-Text
Keywords: pandemic response box; drug repurposing; compound screen; SARS-CoV-2; Retro-2.1; remdesivir; Vero E6; Calu-3 pandemic response box; drug repurposing; compound screen; SARS-CoV-2; Retro-2.1; remdesivir; Vero E6; Calu-3
Show Figures

Figure 1

MDPI and ACS Style

Holwerda, M.; V’kovski, P.; Wider, M.; Thiel, V.; Dijkman, R. Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. Microorganisms 2020, 8, 1872. https://doi.org/10.3390/microorganisms8121872

AMA Style

Holwerda M, V’kovski P, Wider M, Thiel V, Dijkman R. Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. Microorganisms. 2020; 8(12):1872. https://doi.org/10.3390/microorganisms8121872

Chicago/Turabian Style

Holwerda, Melle; V’kovski, Philip; Wider, Manon; Thiel, Volker; Dijkman, Ronald. 2020. "Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro" Microorganisms 8, no. 12: 1872. https://doi.org/10.3390/microorganisms8121872

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop